R&D News | pharmaphorum

News

Novartis reveals more data behind Pluvicto expansion bid

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

News

Another LAG-3 setback as Regeneron drug fails phase 3 trial

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

News

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

News

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

Novartis reveals more data behind Pluvicto expansion bid

Another LAG-3 setback as Regeneron drug fails phase 3 trial

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

AZ cues up broader use of Imfinzi in bladder cancer

Readout for AZ's hypoparathyroidism drug raises questions

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks